Biocon Biologics | Business Upturn

Latest Articles

Biocon Biologics gets marketing authorisation from EC for Denosumab Biosimilars Vevzuo and Evfraxy

Corporates · Jul 3, 2025

blank

Biocon Biologics crosses 100 million insulin cartridge deliveries in Malaysia

Corporates · Jun 30, 2025

blank

Biocon subsidiary gets Health Canada nod for YESAFILI

Corporates · Jun 27, 2025

blank

Biocon Biologics partners with NCSM to launch Cancer Patient Assistance Program in Malaysia

Corporates · Jun 24, 2025

blank

Biocon Biologics secures insulin supply contract extension from Malaysian MoH

Corporates · May 22, 2025

blank

Biocon Biologics secures European Commission approval for its Ustekinumab Biosimilar

Corporates · Feb 18, 2025

blank

Biocon Biologics highlights pathways to boost biosimilar adoption in LMICs

Corporates · Oct 8, 2024

By Aditya Bhagchandani

blank

Biocon’s subsidiary refinances USD 1.1 Billion long-term debt through USD bonds and new syndicated facility

Corporates · Oct 3, 2024

By Aditya Bhagchandani

blank

Biocon Biologics announces pivotal Phase 3 results on Adalimumab Interchangeability at EADV 2024 Congress

Corporates · Sep 25, 2024

blank

Biocon Biologics set to raise $950 million through overseas bonds

Corporates · Sep 14, 2024

By Aditya Bhagchandani

blank

Biocon Biologics secures exclusive distribution rights for Adalimumab Biosimilar in Japan

Business · Dec 22, 2023

By Dimple Gehlot

blank

Pandemic hits Biocon: 18% drop in net profit, MD Christiane Hamacher resigns & shares drop 9.11%

Business · Jan 22, 2021

By Ruchira Sonawat